{
  "id": "adv_mhgap#management_85aac9ef",
  "content": "Serious: orthostatic hypotension, extrapyramidal side\neffects (EPS), ECG changes (prolonged QT interval),\nweight gain, galactorrhea, amenorrhea, Neuroleptic\nmalignant syndrome (NMS).\nRISPERIDONE Start 1 mg daily. Common: sedation, dizziness, tachycardia. Caution in patients with: cardiac disease.\nIncrease to 2-6 mg daily (maximum 10 mg).\nRoute: p.o. Serious: orthostatic hypotension, metabolic effects (elevated Drug-drug interactions: carbamazepine can reduce levels of\nlipids, insulin resistance, weight gain), EPS, elevated prolactin, risperidone, whereas fluoxetine can increase levels.\nsexual dysfunction, NMS.\nCHLORPROMAZINE Start 25-50 mg daily. Common: sedation, dizziness, blurred vision, dry mouth, Contraindications: impaired consciousness, bone marrow depression,\nIncrease to 75-300 mg daily (up to 1000 mg urinary retention, constipation, tachycardia. pheochromocytoma.\nmay be necessary for severe cases).\nRoute: p.o. Serious: orthostatic hypotension, syncope, EPS, Caution in patients with: respiratory disease, kidney disease, liver\nphotosensitivity, weight gain, galactorrhea, amenorrhea, disease, glaucoma, urinary retention, cardiac disease, long QT syndrome\nsexual dysfunction, priapism, NMS, agranulocytosis, or taking QT-prolonging medications. Monitor ECG if possible.\njaundice.\nDrug-drug interactions:\n– Increases effects of blood pressure lowering medications.\n– Lowers blood pressure if combined with epinephrine.\n– Levels may be increased by antimalarials including quinine.\nFLUPHENAZINE Start 12.5 mg. Common: sedation, dizziness, blurred vision, dry mouth, Contraindications: impaired consciousness, parkinsonism.",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "stress",
      "management"
    ],
    "is_clinical": true,
    "is_advice": true
  },
  "index_text": "General — Management Serious: orthostatic hypotension, extrapyramidal side\neffects (EPS), ECG changes (prolonged QT interval),\nweight gain, galactorrhea, amenorrhea, Neuroleptic\nmalignant syndrome (NMS).\nRISPERIDONE Start 1 mg daily. Common: sedation, dizziness, tachycardia. Caution in patients with: cardiac disease.\nIncrease to 2-6 mg daily (maximum 10 mg).\nRoute: p.o. Serious: orthostatic hypotension, metabolic effects (elevated Drug-drug interactions: carbamazepine can reduce levels of\nlipids, insulin resistance, weight gain), EPS, elevated prolactin, risperidone, whereas fluoxetine can increase levels.\nsexual dysfunction, NMS.\nCHLORPROMAZINE Start 25-50 mg daily. Common: sedation, dizziness, blurred vision, dry mouth, Contraindications: impaired consciousness, bone marrow depression,\nIncrease to 75-300 mg daily (up to 1000 mg urinary retention, constipation, tachycardia. pheochromocytoma.\nmay be necessary for severe cases).\nRoute: p.o. Serious: orthostatic hypotension, syncope, EPS, Caution in patients with: respiratory disease, kidney disease, liver\nphotosensitivity, weight gain, galactorrhea, amenorrhea, disease, glaucoma, urinary retention, cardiac disease, long QT syndrome\nsexual dysfunction, priapism, NMS, agranulocytosis, or taking QT-prolonging medications. Monitor ECG if possible.\njaundice.\nDrug-drug interactions:\n– Increases effects of blood pressure lowering medications.\n– Lowers blood pressure if combined with epinephrine.\n– Levels may be increased by antimalarials including quinine.\nFLUPHENAZINE Start 12.5 mg. Common: sedation, dizziness, blurred vision, dry mouth, Contraindications: impaired consciousness, parkinsonism. Serious: orthostatic hypotension, extrapyramidal side\neffects (eps), ecg changes (prolonged qt interval),\nweight gain, galactorrhea, amenorrhea, neuroleptic\nmalignant syndrome (nms). risperidone start 1 mg daily."
}